Canidryl 100 mg Tablets for Dogs

Kraj: Wielka Brytania

Język: angielski

Źródło: VMD (Veterinary Medicines Directorate)

Składnik aktywny:

Carprofen

Dostępny od:

Chanelle Pharmaceuticals Manufacturing Ltd

Kod ATC:

QM01AE91

INN (International Nazwa):

Carprofen

Forma farmaceutyczna:

Tablet

Typ recepty:

POM-V - Prescription Only Medicine – Veterinarian

Grupa terapeutyczna:

Dogs

Dziedzina terapeutyczna:

Anti Inflammatory NSAID

Status autoryzacji:

Authorized

Data autoryzacji:

2006-12-12

Charakterystyka produktu

Revised: December 2019
AN: 00610/2019
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canidryl 100 mg Tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENT
Carprofen
100.0 mg/tablet
EXCIPIENTS
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A white to off white round shape tablets with a cross break line on
one side.
The tablets can be divided into halves or quarters.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative
joint
disease.
As
a
follow
up
to
parenteral
analgesia
in
the
management of post-operative pain following soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in cats.
Do not use in case of hypersensitivity to active substance or to any
of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastro-intestinal ulceration or bleeding, or where
there is evidence of a
blood dyscrasia.
Refer to section 4.7.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5
4.5
SPECIAL PRECAUTIONS FOR USE
Revised: December 2019
AN: 00610/2019
Page 2 of 6
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk.
If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a potential
risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAIDs
can
cause
inhibition
of
phagocytosis
and
hence
in
the
treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Some NSAIDs may be highly bound to plasma proteins and compete with
other
highly